Singulair Lawsuit February 2024 Update – Forbes Advisor – Technologist

Singular lawsuits are being filed because some patients claim the allergy medication has dangerous risks they were not adequately warned about. The FDA received case reports linking the medication to injuries, including suicide, neuropsychiatric injuries and mental health illnesses. In some cases, these side effects resolved after stopping the drug, but in others, they persisted.

The FDA began investigating a link between Singulair and mood and behavior changes, including suicidal thoughts and suicide, in 2008. In 2009, The FBA added information to the Precautions part of the drug’s prescribing information to warn of some of these risks.

In March of 2020, the FDA took action in response to concerns about montelukast. While prescribing information already included a warning about potential mental health complications associated with the use of the prescription medication, the FDA determined that patients deserved stronger warnings.

The FDA ordered a “Boxed Warning,” which is the most prominent warning label, be added to prescribing information. The Administration also mandated the creation of a new patient medication guide to provide educational information to patients about the potential dangers of the drug and the possible consequences to mental health.

Unfortunately, some patients already experienced neuropsychiatric injuries and felt they had not been adequately warned by Merck & Co. As a result, patients—or the family members of those affected—have begun filing lawsuits to pursue a claim for compensation for their damages.

Affected plaintiffs claim that Merck knew from early research about the dangers and downplayed the risks to both patients and regulators. Plaintiffs are supporting these allegations with research from a cell biologist, Julia Marschallinger, whose team discovered that the drug’s distribution within the brain was more significant than the drug’s label implied.